Management of multiple myeloma in older adults: Gaining ground with geriatric assessment.
Multiple myeloma increases in incidence with age. With the aging of the population, the number of cases of multiple myeloma diagnosed in older adults each year will nearly double in the next 20years. The novel therapeutic agents have significantly improved survival in older adults, but their outcomes remain poorer than in younger patients. Older adults may be more vulnerable to toxicity of therapy, resulting in decreased dose intensity and contributing to poorer outcomes. Data are beginning to emerge to aid in identifying which individuals are at greater risk for toxicity of therapy; comorbidities, functional limitations, and age over 80years are among the factors associated with greater risk. Geriatric assessment holds promise in the care of older adults with multiple myeloma, both to allow modification of treatment to prevent toxicity, and to identify vulnerabilities that may require intervention. Emerging treatments with low toxicity and attention to individualizing therapy based on geriatric assessment may aid in further improving outcomes in older adults with multiple myeloma.
Washington University School of Medicine, St. Louis, MO, USA. Electronic address: twildes@wustl.edu.
Tanya M
TM
Wildes
University of Michigan School of Medicine, Ann Arbor, MI, USA.
Erica
E
Campagnaro
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D019468:Disease Management; D000073496:Frailty / Q000150:complications / Q000175:diagnosis*; D015577:Geriatric Assessment; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*
D000970:Antineoplastic Agents; D005938:Glucocorticoids
Aging; Cancer; Elderly; Geriatric assessment; Multiple myeloma; Treatment